Company intelligence

SYRE

Spyre Therapeutics, Inc. · NASDAQ · Healthcare

Price$90.33-2.17% · −$2.00

Market cap8.34BEquity value

P / E-46.3Trailing ratio

Volume502.89KLatest session

Market data

SYRE price chart

TradingView

Related signals

1 min delayed

Browse public SYRE signals with their source context and measured market impact. Open any signal for its permanent analysis page.

SYREJun 15, 2026+3.37% since signal

Spyre Therapeutics hits primary endpoint in mid-stage bowel disease trial

Spyre announced its bowel disease drug met the primary endpoint in a mid-stage trial, with a significant reduction in disease severity. The topline result could accelerate Phase 3 plans and attract potential partnerships or funding, creating a near-term catalyst for SYRE.

View signal analysis

SYREApr 13, 2026-1.88% since signal

Spyre Therapeutics Shows Bullish Momentum Amid Promising Drug Trial Results

Spyre Therapeutics is experiencing bullish market momentum, supported by promising Phase 2 trial results for its drug SPY001, aimed at treating moderate-to-severe ulcerative colitis. With strong efficacy data and analysts raising price targets, the stock is approaching a pivotal $70 resistance level which could influence short-term trading strategies and profit-taking actions.

View signal analysis

Research